AKT1 and neoplasm: By specifically targeting FGFRs, these small-molecule inhibitors effectively block crucial downstream cascades, primarily the PI3K/Akt and MAPK pathways, which are essential for tumor progression (Table 2) (Clark and Soriano, 2024; Katoh and Nakagama, 2014).